Establishment and analysis of artificial neural network diagnosis model for coagulation-related molecular subgroups in coronary artery disease.
Source check: Source checked. Not independent scientific confirmation.
Finding: The study used feature selection and an artificial neural network to distinguish two coagulation-related molecular subgroups in coronary artery disease, then characterized their immune and pathway differences. This is a molecular-subgroup analysis, not evidence of clinical benefit.
Technology: Random-forest/LASSO feature selection and an artificial neural network were used to classify coagulation-related CAD molecular subgroups.
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- A learned classifier enabled a distinction between coagulation-related CAD molecular subgroups and comparison of their molecular profiles.
- Test and result
- The analysis reports two molecular subgroups with differing immune and pathway profiles, based on coagulation-related gene features.
- Limitation / still unknown
- The authors used training and validation datasets; the result is a computational subgroup distinction and does not establish clinical utility or causal mechanisms.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2024.1351774/full
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review date: 22 Nov 2026. Review scope: Primary Frontiers full text and Europe PMC full-text record; publication date checked against primary metadata..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.